The Affiliated Xuzhou Rehabilitation Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Department of Rehabilitation Medicine, XuZhou Central Hospital, Xuzhou, Jiangsu, China.
BMJ Open. 2020 Dec 8;10(12):e041184. doi: 10.1136/bmjopen-2020-041184.
Both physical and mental disorders may be exacerbated in patients with COVID-19 due to the experience of receiving intensive care; undergoing prolonged mechanical ventilation, sedation, proning and paralysis. Pulmonary rehabilitation is aimed to improve dyspnoea, relieve anxiety and depression, reduce the incidence of related complications, as well as prevent and improve dysfunction. However, the impact of respiratory rehabilitation on discharged patients with COVID-19 is currently unclear, especially on patients who have been mechanically ventilated over 24 hours. Therefore, we aim to investigate the efficacy of respiratory rehabilitation programmes, initiated after discharge from the intensive care unit, on the physical and mental health and health-related quality of life in critical patients with COVID-19.
We have registered the protocol on PROSPERO and in the process of drafting it, we strictly followed the checklist of Preferred Reporting Items for Systematic Review and Meta-Analysis Potocols. We will search the PubMed, EMBASE, Web of Science, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, WanFang, VIP information databases and Chinese Biomedical Literature Database. Additionally, ongoing trials in the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov and ISRCTN registry will be searched as well. Studies in English or Chinese and from any country will be accepted regardless of study design. Two review authors will independently extract data and assess the quality of included studies. Continuous data are described as standard mean differences (SMDs) with 95% CIs. Dichotomous data from randomised controlled trials are described as risk ratio(RR) with 95% CIs; otherwise, it is described as odds ratio(OR) with 95% CIs. I and the Cochrane's Q statistic will be used to conduct heterogeneity assessment. The quality of evidence of main outcomes will be evaluated according to the Grading of Recommendations, Assessment, Development and Evaluation(GRADE) criteria. When included studies are sufficient, we will conduct subgroup analysis and sensitivity analysis; the publication bias will be statistically analysed using a funnel plot analysis and Egger's test.
Our review, planning to include published studies, does not need the request to the ethical committee. The final results of this review will be published in a peer-reviewed journal after completion.
No patient involved.
CRD42020186791.
由于接受重症监护、长时间机械通气、镇静、俯卧位和瘫痪等经历，COVID-19 患者的身体和心理障碍可能会加重。肺康复旨在改善呼吸困难，缓解焦虑和抑郁，降低相关并发症的发生率，并预防和改善功能障碍。然而，目前尚不清楚呼吸康复对 COVID-19 出院患者的影响，特别是对接受机械通气超过 24 小时的患者。因此，我们旨在研究重症 COVID-19 患者从重症监护病房出院后开始的呼吸康复计划对其身心健康和健康相关生活质量的疗效。
我们已在 PROSPERO 上注册了该方案，在起草过程中，我们严格按照系统评价和荟萃分析报告的首选报告项目清单进行。我们将检索 PubMed、EMBASE、Web of Science、Cochrane 中央对照试验注册中心、中国知网、万方、维普信息数据库和中国生物医学文献数据库。此外，还将检索世界卫生组织国际临床试验注册平台、ClinicalTrials.gov 和 ISRCTN 注册处正在进行的试验。我们将接受来自任何国家的英语或中文研究。两名综述作者将独立提取数据并评估纳入研究的质量。连续数据以标准均数差（SMD）表示，并附有 95%置信区间（CI）。随机对照试验的二分类数据用风险比（RR）表示，并附有 95%置信区间（CI）；否则，用比值比（OR）表示，并附有 95%置信区间（CI）。我们将使用 I²和 Cochrane's Q 统计量进行异质性评估。主要结局的证据质量将根据推荐、评估、发展和评估（GRADE）标准进行评估。当纳入研究充分时，我们将进行亚组分析和敏感性分析；使用漏斗图分析和 Egger 检验对发表偏倚进行统计学分析。
我们的综述计划纳入已发表的研究，因此不需要向伦理委员会提出请求。完成后，我们将在同行评议的期刊上发表本综述的最终结果。
不涉及患者。
PROSPERO 注册号：CRD42020186791。
